The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03846856

Enrollment

Registered

2019-02-20

Start date

2019-04-30

Completion date

2021-03-31

Last updated

2019-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Brief summary

The aim of this study is to evaluate the insulin-like growth factor (IGF) axis involvement in the immune tumor microenvironment in ovarian cancer.

Interventions

OTHERBiopsy

Biopsy taken during surgical procedure

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women diagnosed with epithelium ovarian cancer who have undergone surgery

Exclusion criteria

* Pregnant women

Design outcomes

Primary

Measure	Time frame	Description
Involvement of IGF Axis in Ovarian Cancer	Two years	Ovarian cancer specimens taken during surgical procedures will be evaluated and analyzed by flow cytometry assays to determine the involvement of the IGF axis in the immune tumor microenvironment in ovarian cancer

Countries

Israel

Contacts

Primary ContactHagit Stolz, DVM

hagitst@hy.health.gov.il972-4-7744335

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026